Developed by Teikoku Pharma USA, a subsidiary of Teikoku Seiyaku, the Aricept Patch is a weekly transdermal patch intended to provide an alternative formulation for Alzheimer’s patients.
Teikoku Pharma USA and Eisai were seeking approval of the weekly Aricept Patch for the treatment of mild, moderate and severe stages of Alzheimer’s disease.
Eisai said it will work with Teikoku Pharma USA to assess the CRL and determine next steps.
Eisai, which holds the US marketing rights, will co-promote the Aricept Patch with Pfizer if approved.